Stand Up To Cancer has launched two initiatives to increase minority representation in cancer clinical trials by amending its grant application requirements and funding a new research team focused on diversity and inclusion.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
